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Abstract
Background: Very little is known of the regulation of the function of human osteoclasts, largely
due to the virtual impossibility of obtaining human osteoclasts ex vivo. It has recently become
possible to generate human osteoclasts in vitro, by incubation of peripheral blood mononuclear cells
(PBMCs) in macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear
factor-κB ligand (RANKL). However, the assays at present available do not distinguish clearly
between the distinct effects of agents on differentiation and function.
Materials and methods: We developed a novel assay for resorptive function of human
osteoclasts that minimizes inter-assay variability by using each culture as its own baseline, and that
minimizes the confounding effects of agents on differentiation by assessing resorptive function over
a short test period. In this assay, the development of resorptive activity is monitored in sample
cultures. When resorption is underway, bone resorption (measured as the release of the C-
terminal telopeptide degradation product of type I collagen (CTX-I) into the supernatant) is
compared before vs after incubation for 1–24 h in test agent.
Results: Using this assay, we found that changes in bone resorption could be detected using
substantially fewer cultures per variable. Moreover, we could detect effects of agents on resorption
within 1 h of addition, a time sufficiently short that a change in release is likely to reflect an effect
on function rather than on differentiation.
Conclusion: The assay makes it possible to distinguish the effects of agents on osteoclastic
function, independent of their effects on differentiation.
Background
The maintenance of skeletal integrity depends on contin-
ual resorption of bone by osteoclasts and its replacement
by osteoblasts. Recently, there have been considerable
advances in our understanding of the mechanisms
through which osteoclast formation is regulated [1-3]. In
contrast, little is known of the mechanisms that modulate
their activity once formed, even although this is a major
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component of the regulation of bone resorption. Thus,
after systemic administration of hormones such as PTH or
CT, osteoclasts show morphological evidence of an
increase or decrease in activity, with a corresponding
change in plasma calcium concentration, within 30 min,
while a change in osteoclast number is not detectable
until 24 h later [4]. This shows that bone resorption is reg-
ulated not only through modulation of the number of
osteoclasts but also by modulation of the resorptive activ-
ity of existing osteoclasts. It seems likely that agents exert
differential actions on these distinct processes.
It is virtually impossible to obtain human osteoclasts ex
vivo with which to address this question. In their absence,
human osteoclastic cells can be generated in vitro by incu-
bation of peripheral blood mononuclear cells (PBMCs) in
macrophage colony-stimulating factor (M-CSF) and
receptor activator of nuclear factor-kB ligand (RANKL) on
plastic culture surfaces or on bone/dentine slices [5,6].
However, although such culture systems provide powerful
insights into the regulation of osteoclastic differentiation,
they do not clearly distinguish between the effects of
agents on differentiation and function. For example,
resorption of bone slices in such culture systems is typi-
cally observed after 14–21 days of incubation [7-10]. If a
putative resorption modulator is added to such cultures
for a brief period, effects on resorption, classically meas-
ured as the area of bone surface excavated, will be
observed against a baseline of prior resorption; and if the
modulator is added over a longer period, it will be diffi-
cult to distinguish effects on function from those on dif-
ferentiation.
Recently, it has become possible to measure bone resorp-
tion as the release into culture supernatants of products of
bone solubilization, the concentration of which has been
shown to correlate with bone resorption [11]. This
approach has the advantage that the amount released
reflects the amount of bone resorbed since the last change
of culture medium. This avoids the results being masked
by the baseline of prior resorption. However, even in such
assays, bone resorption is measured over a period of 3
days [12,13], so that an unknown and potentially sub-
stantial component of an observed change in resorptive
activity might have been due to an effect of the test agent
on differentiation rather than function.
The difficulties in the interpretation of resorption data
mentioned above are compounded by the length of time
it normally takes for osteoclastic differentiation to occur:
the long incubation times magnify small initial differ-
ences between cultures, and in our experience can lead to
substantial inter-culture variability. This variability
increases the number of cultures required per variable,
and because relatively small numbers of monocytes are
available from a given donor, the number of variables that
can be studied in each experiment is in practice severely
limited.
We therefore developed a novel assay that minimizes the
confounding effects of agents on differentiation by meas-
uring resorption over a shorter period; and that minimizes
inter-culture variability by using each culture as its own
baseline. In this assay, sample cultures are inspected to
monitor the development of actively resorbing osteo-
clasts. When resorption is underway, release of products
of bone resorption is compared before vs after incubation
for 1–24 h with test agent. Using this approach, we found
that changes in bone resorption could be detected using
substantially fewer cultures per variable; and that effects
of agents on resorption could be detected within 1 h of
addition, a time sufficiently short that a change in release




Cells were incubated in MEM with Earle's salts (Invitro-
gen, Paisley, UK), supplemented with 10% fetal calf
serum (FCS), 2 mM glutamine, 100 IU/ml benzylpenicil-
lin, and 100 μg streptomycin (all Sigma, Poole, Dorset,
UK) (MEM/FCS). Recombinant human M-CSF and solu-
ble recombinant murine RANKL were from Insight Bio-
technology (Wembley, Middlesex, UK). The specific
cathepsin K inhibitors MV061194, MV061748,
MV061940, MV061645 and MSX-081 were provided by
Medivir UK (Cambridge, UK). Cortical bovine bone slices
(4 × 4 × 0.1 mm) were prepared as previously described
[14]. Salmon CT, E64 and all remaining reagents were
from Sigma unless otherwise stated.
Osteoclast generation
Heparinized blood was obtained from healthy human
male or female volunteers (aged 22 – 57) with the consent
of St George's Ethical Committee. The blood was layered
over Histopaque-1077 and centrifuged for 30 min at 400
g. The opaque interface containing mononuclear cells
(PBMCs) was collected with a pasteur pipette, washed in
PBS, then resuspended in MEM/FCS. 5 × 105 cells were
added per well to a 96-well plate, each well of which con-
tained a bone slice. The cultures were incubated in a total
volume of 200 μl MEM/FCS containing M-CSF (50 ng/ml)
and RANKL (30 ng/ml) for 24 h at 37°C in 5% CO2 in
humidified air. Bone slices were then removed from the
wells and placed in the wells of a 24-well plate, in 1 ml of
MEM/FCS containing M-CSF and RANKL at the above
concentrations, before continued incubation. Cultures
were fed three times per week by replacing 60% of the
medium with fresh medium and cytokines.Journal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
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To monitor cultures for the development of resorptive
function, sample bone slices were removed at intervals,
fixed in 10% formalin and stained using toluidine blue
(0.1% for 1 min). Bone slices were then inspected by light
microscopy for the presence of osteoclasts and excava-
tions (see Fig. 1). When excavation was deemed sufficient,
the remaining cultures were subjected to the osteoclast
resorption assay.
Osteoclast Resorption Assay
After generation of resorptive osteoclasts (as detected
above), bone slices were removed from the 24-well plates,
washed in PBS, placed in the wells of a 96-well plate, and
incubated for 2 or 24 h in 100 μl of fresh MEM/FCS con-
taining M-CSF and RANKL. All the culture medium was
removed after this period of incubation and stored frozen.
Bone slices were washed again in PBS and transferred to
new 96-well plates, the wells of which contained 100 μl of
fresh MEM/FCS containing M-CSF and RANKL, together
with test agent or vehicle control unless otherwise stated.
Supernatants were collected and stored frozen after a fur-
ther 1–24 h of incubation.
The resorption activity of the cultures was determined by
quantifying the C-terminal telopeptide degradation prod-
uct of type I collagen (CTX-I/CrossLaps®) (Nordic Bio-
science Diagnostics A/S, Herlev, Denmark) in the culture
supernatants. Enzyme-linked immunosorbent assay
(ELISA) was performed according to the manufacturer's
instructions.
In some experiments, when the resorption assay had been
completed, bone slices were further analyzed for visuali-
zation of cells and excavations using toluidine blue, tar-
trate-resistant acid phosphatase (TRAP) cytochemistry
and reflected light or scanning electron microscopy. In
other experiments, the total quantity of TRAP present in
the cells at the end of the culture was assessed by enzyme
assay of TRAP in cell lysates.
Reflected Light and Scanning Electron Microscopy
After incubation, bone slices were immersed in 10% (v/v)
sodium hypochlorite for 10 min to remove cells. The bone
slices were then washed in water, air-dried, mounted and
sputter-coated with gold. Bone slices on stubs were
inspected in a scanning electron microscope (S90: Cam-
bridge Instruments, Cambridge, UK). The extent of bone
resorption on bone slices mounted onto microscope
slides was quantified by counting the number of grid
intersections in an eyepiece graticule that overlay an area
of bone resorption using reflected light microscopy.
Enzyme Assay for TRAP
After removal of supernatant, bone slices were washed in
PBS, transferred to fresh wells of a 96-well plate and incu-
bated in 100 μl 0.1% Triton in water (v/v) for 10 min.
Osteoclast formation from human PBMCs Figure 1
Osteoclast formation from human PBMCs. PBMCs were incubated with M-CSF and RANKL on bone slices for 7 days. Sample 
bone slices were taken and stained with toluidine blue (A, B) to assess multinuclear cell formation and bone resorption (bar = 
100 μm). In A, virtually all of the cells shown are multinuclear, with only a very occasional cell (white arrows) remaining mono-
nuclear. B: at higher magnification many excavations (black arrows) can be visualized as darkly-staining areas beneath the oste-
oclasts. C: SEM of bone slice after removal of cells. Almost the entire surface shows excavation, with only occasional islands of 
unresorbed surface remaining.Journal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
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TRAP enzyme activity was measured by the conversion of
p-nitrophenyl phosphate to p-nitrophenol in the presence
of sodium tartrate. 80 μl of each lysate, diluted appropri-
ately, was added to 96-well plate wells containing 80 μl
0.09 M citrate buffer (pH 4.8) with 20 mM phosphatase
substrate and 80 mM tartaric acid and incubated at room
temperature for 40 min. The reaction was stopped by
addition of 40 μl of 0.5 M sodium hydroxide. Optical
absorbance was measured at 405 nm on an Opsys MR
plate reader (Thermo Electron Corporation, Basingstoke,
Hampshire, UK) against a standard curve of p-nitrophe-
nol.
Statistical Analysis
All data are expressed as mean ± standard error of mean,
of four replicate cultures, unless otherwise stated. The sig-
nificance of differences between control and experimental
groups was assessed by Student's t test or ANOVA (Dun-
nett's Multiple Comparison Test). Differences were con-
sidered significant if p < 0.05
Results
Optimization of osteoclast formation and bone resorption
Previous assays have used an incubation time of three
days to measure CTX-I release [12,13]. To distinguish
between actions of agents on the differentiation and func-
tion of osteoclasts requires as short a sampling period as
possible, and this in turn depends upon optimizing the
rate of bone resorption in the cultures. The optimal den-
sity of cells for osteoclast generation from human PBMCs
has been established [6,8]. It is also essential to optimize
choice of donor, because there is considerable variation in
the ability of PBMCs from different donors to generate
osteoclasts. We also found that efficient osteoclastic differ-
entiation was supported by only a minority of serum
batches. To optimize the assay, our strategy was to test the
ability of 4–5 serum batches to support osteoclast forma-
tion from the blood of 4–5 donors. This approach identi-
fied a single combination of donor and serum that
efficiently generated osteoclasts. We found that the batch
of serum so identified as optimal was able to similarly
support efficient osteoclast formation in approximately
20% of donors; and that donors showed a reproducible
ability for the efficient generation of osteoclasts. Thus, in
our experience, some donors seemed able to generate only
small or very small numbers of osteoclasts whatever
serum batch was used; while some sera did not support
osteoclast formation from any of the donors. Optimal
combinations of donor and serum were thus identified
that generated cultures in which virtually all cells were
multinuclear, and almost the entire bone surface was
excavated within 7 days (see Fig. 1)
Optimization of resorption assay
We noted that there was frequently considerable variation
in the extent of bone resorption on different bone slices
incubated under identical conditions in the same experi-
ment (Fig. 2). This variability might reflect variation in the
properties of individual bone slices. An alternative expla-
nation is that variability might be due to the smallness of
the numbers of osteoclast precursors in our cultures: these
are known to represent a very small proportion (<1%) of
PBMCs [15], and if the number of precursors in each cul-
ture is very small, random variation in this number could
lead to appreciable inter-culture differences in osteoclast
formation. A further possibility is that osteoclast forma-
tion in such cultures might reflect a cell-density depend-
ent component in the differentiation of PBMCs to
osteoclasts, which magnifies small starting differences in
the number or distribution of PBMCs. Whatever the
explanation for the variability, it represents an obstacle to
the practical application of assays of osteoclast differenti-
ation and function.
We hypothesized that the effect of inter-culture variability
could be minimized by a longitudinal rather than cross-
sectional assay design. These alternative approaches were
compared in an assay using an inhibitor of cathepsin K, an
enzyme crucial to the degradation of collagen during
bone resorption by osteoclasts (Fig. 3). The inter-culture
variability in CTX-I levels in samples taken after the initial
24 h incubation period lead to considerable variation in
the means for each group (Fig. 3A). This inter-culture var-
iability confounds the dose-response analysis derived
from the CTX-I concentrations obtained after incubation
in the inhibitor (Fig. 3B). However, the effect of inter-cul-
ture variability is reduced when the initial 24 h period is
taken as a baseline for the second sample from the same
culture (Fig. 3C). Further examples of the application of
this approach to the assessment of the potency of inhibi-
tors of bone resorption are shown in Fig. 4.
To assess the relative statistical power of the longitudinal
vs the cross-sectional approach, we used data from the
control groups of assays similar to those shown in Fig. 3.
We compared the power of CTX-I data derived from the
longitudinal measurements with the power of data
derived from the second 24 h incubation alone. We
found, in data from 6 consecutive assays, that to have a
95% chance of detecting a change in the mean of 50%
required 25 (± 20) cultures if a single CTX-I measurement
is used for each culture, but only 3.4 (± 2.1) cultures if cul-
tures are sampled longitudinally.
The high cost of CTX-I assays led us to test alternative
approaches that might provide a measure of the osteoclas-
tic content of cultures that would substitute for the first
CTX-I reading. It might be that the TRAP content of lysatesJournal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
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reflects the resorptive capacity of cultures. We therefore
tested the relationship between the first of the pair of CTX-
I readings, and the TRAP in the lysate of the corresponding
culture after incubation in either control medium or the
cysteine protease inhibitor E64 (10-7 M – 10-5 M). We
found a strong correlation between initial CTX-I and
TRAP in cultures incubated in control medium (r2 = 0.96)
(n = 24), but the correlation was less clear for cultures
incubated in E64 (r2 = 0.52) (n = 24). This conforms to
our previous experience, that the TRAP content of cells is
influenced by agents that modulate bone resorption [16]:
TRAP is released during bone resorption, and perturba-
tion of resorption increases or decreases the amount that
remains in the cell. Thus, measurement of the TRAP con-
tent of lysates is an unreliable substitute for the initial
CTX-I measurement.
We tested the ability of the assay to detect changes in bone
resorption over shorter time periods (Fig. 5). In these
experiments, bone slices were washed after osteoclasts
had formed, transferred to new 96-well plates, and incu-
bated in fresh medium containing M-CSF and RANKL.
After 2 h of incubation this supernatant was removed for
CTX-I assay, and replaced with medium containing con-
trol or test reagents, and incubated for a further 1 h. This
supernatant was then itself removed for assay, and the
process repeated with further incubation periods of 1 and
2 h. We found that suppression of bone resorption could
be detected within 1 h of incubation of osteoclasts in
MV061194 (3 × 10-7 M), a cathepsin K inhibitor, and
within 2 h of incubation in salmon CT (10 ng/ml). This
result additionally suggests that inhibition of bone resorp-
tion by the cathepsin K inhibitor has a more rapid onset
than inhibition by CT. This might be because intracellular
degradation of endocytosed matrix fragments continues
to completion despite cell-inhibition, while the effects of
the (membrane-permeant) enzyme inhibitor are essen-
tially immediate.
Discussion
Very shortly after administration of hormones such as CT
or PTH, osteoclasts show morphological evidence in vivo
of changes in functional activity that correspond to
changes in plasma calcium concentration [4]. Only much
later do osteoclast numbers change. Thus, modulation of
the activity of existing osteoclasts is a major component of
the regulation of bone resorption. Recently, significant
advances have been made in elucidating the mechanisms
that govern osteoclastogenesis [1,3,17]. In contrast, much
less is known about how the resorptive activity of osteo-
clasts is regulated.
This is because human osteoclasts are essentially unavail-
able ex vivo. In their absence, osteoclasts can be generated
in vitro, but osteoclast formation from human PBMCs typ-
ically takes 14–21 days [7-10]. Thus, if a putative resorp-
tion modulator is added to such cultures for a brief
period, effects on resorption, measured as the area of bone
surface excavated, will be observed against a high baseline
of prior resorption; and if the modulator is added over a
longer period, any change in resorption might be second-
ary to effects on differentiation.
Quantification of bone resorption on individual bone slices in  the same experiment Figure 2
Quantification of bone resorption on individual bone slices in 
the same experiment. A single preparation of PBMCs was 
added to multiple bone slices. Bone slices were incubated in 
different wells with M-CSF and RANKL for 10 days. At the 
end of the culture period cells were removed, and the area 
of each bone slice excavated by osteoclasts was measured.Journal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
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This problem is partly circumvented in assays that meas-
ure bone resorption as the release into culture superna-
tants of products of bone solubilization [12,13,18]. This
approach has the advantage that the quantity of solubi-
lized product reflects only the quantity of bone resorbed
since the last change of culture medium. This avoids the
results being obscured by a baseline of prior resorption.
However, even in such assays, bone resorption is meas-
ured over a period of 3 days, so that an unknown and
potentially substantial component of any observed
change in resorptive activity might have been due to an
effect of the test agent on differentiation rather than func-
tion.
A second difficulty is the substantial inter-culture variabil-
ity in osteoclast formation, which might be accentuated
by the prolonged incubation required to form osteoclasts
from PBMCs: long incubation times might magnify small
initial differences between cultures, especially since cells
capable of forming osteoclasts represent only a very small
proportion (<1%) of PBMCs [15], so that random varia-
tion in this number could lead to appreciable inter-culture
differences in osteoclast formation. High inter-culture var-
iability requires more cultures per experimental group,
and this restricts the number of groups that can be studied
in each experiment.
We therefore developed a novel assay that, by addressing
these difficulties, facilitates the measurement of osteoclast
function independent of differentiation. First, we opti-
mized bone resorption, since if there is more bone resorp-
tion it can be measured over a shorter period. Short
measurement periods minimize the confounding effects
of agents on differentiation. We optimized bone resorp-
tion by optimizing combinations of serum batches and
PBMC-donors. This led to substantially greater and earlier
release of CTX-I antigen, to levels an order of magnitude
greater than previously reported [10,12,13]. This robust
osteoclast formation enabled us to detect and measure
CTX-I released in 1 h of incubation, a time sufficiently
short that any change in resorption is likely to reflect an
effect on osteoclastic function rather than on differentia-
tion. Second, we minimized inter-culture variability by
using each culture as its own baseline. Using this longitu-
dinal approach, we found that changes in bone resorption
could be detected using substantially fewer cultures per
variable.
In view of the significant expense of longitudinal meas-
urements of CTX-I, we tested whether measurement of the
quantity of TRAP in the cell lysates at the termination of
the experiment could substitute for the initial CTX-I assay.
We found that, while TRAP correlated well with the initial
CTX-I reading in control cultures, the correlation in exper-
imental groups in which bone resorption was modulated
was unreliable. We have previously noted that agents that
modulate resorption also modulate lysate TRAP levels
[16]. However, since TRAP release by resorbing osteoclasts
is proportional to the duration of bone resorption, meas-
urement of TRAP might more accurately reflect the osteo-
clast content of the culture in experiments in which
resorption is measured over shorter time intervals.
CTX-I release in the 24 h period before ('basal') (A) and after (B) addition of an inhibitor of cathepsin K, and the same data  expressed (C) as CTX-I released after, as a percentage of that released in the same culture before, incubation in inhibitor Figure 3
CTX-I release in the 24 h period before ('basal') (A) and after (B) addition of an inhibitor of cathepsin K, and the same data 
expressed (C) as CTX-I released after, as a percentage of that released in the same culture before, incubation in inhibitor. 
Results are derived from a single PBMC preparation. n = 4 bone slices per group.Journal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
Page 7 of 9
(page number not for citation purposes)
Application of assay to assessment of potency of cathepsin K inhibitors Figure 4
Application of assay to assessment of potency of cathepsin K inhibitors. Results expressed as CTX-I after incubation in inhibi-
tor for 24 h, as percentage of CTX-I in the same culture measured in the 24 h before addition of the inhibitor ('basal' CTX-I 
release). Mean values (nM) of basal CTX-I groups were (range): A: 112–333; B: 199–379; C: 77–137; D: 185–322. n = 4 cul-
tures per group. * p < 0.05 vs no inhibitor.Journal of Translational Medicine 2006, 4:45 http://www.translational-medicine.com/content/4/1/45
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Conclusion
The short incubation times and the longitudinal sampling
makes the assay we have described a powerful tool with
which to detect and quantify the effects of agents that acti-
vate or modulate the resorptive activity of osteoclasts,
while minimizing the potentially confounding effects of
the same agent on osteoclastic differentiation. The assay
design also reduces the inter-culture variability of resorp-
tion data, compared to previous approaches.
Competing interests
UG and MS are employed by Medivir UK; BS is employed
by Medivir AB. TJC receives consultancy fees from Medivir
UK
Authors' contributions
BK and KF performed all the experimental studies. KF pre-
pared the figures. UG, BS, MS and TJC conceived the assay
approach. UG, BS and MS created the novel inhibitors of
cathepsin K. TJC supervised the experimental work and
wrote the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
BK was supported by the Wellcome Trust, KF by the Arthritis and 
Research Council, and TJC by HEFC. We are grateful to Philip Jackson, Laia 
Crespo and Mark Liley (all of Medivir UK) for preparation of the cathepsin 
K inhibitors.
Short-term effects of resorption-inhibitors on release of CTX-I by human osteoclasts Figure 5
Short-term effects of resorption-inhibitors on release of CTX-I by human osteoclasts. When bone resorption was underway, 
as judged from inspection of sample bone slices, bone slices were washed and transferred to new wells containing fresh 
medium containing M-CSF/RANKL. After 2 h of incubation this supernatant was removed for CTX-I assay, and replaced with 
medium containing M-CSF/RANKL, together with test reagents or vehicle. Cultures were incubated for a further 1 h. This 
supernatant was then itself removed for assay, and the process repeated with further incubation periods of 1 and 2 h. CTX-I 
release was calculated as nM released per hour, and expressed as a percentage of that released per hour before the test peri-
ods. CTX-I release before test period (nM): controls: 22 ± 2.5; salmon CT (10 ng/ml): 35 ± 12; MV061194 3 × 10-7 M): 34 ± 13. 
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